Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Veillon, C. Payan, C. Gaudy, A. Goudeau, F. Lunel (2003)
[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].Pathologie-biologie, 52 9
Akuta (2006)
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral loadJ Med Virol, 78
Theamboonlers (2002)
Molecular characterization of hepatitis C virus (HCV) core region in HCV- infected Thai blood donorsActa Virol, 46
Zeuzem (1997)
Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfaHepatology, 25
Murayama (2007)
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1BJ Med Virol, 79
Gale (1997)
Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A proteinVirology, 30
Zeuzem (2004)
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3J Hepatol, 40
Mangia (2005)
Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3N Engl J Med, 352
Moradpour (2005)
Function follows form: the structure of the N-terminal domain of HCV NS5AHepatology, 42
Akuta (2005)
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapyIntervirology, 48
Enomoto (1995)
Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A regionJ Clin Invest, 96
Tellinghuisen (2004)
The NS5A protein of hepatitis C virus is a zinc metalloproteinJ Biol Chem, 279
Chayama (1997)
Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infectionHepatology, 5
Okanoue (2009)
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center studyJ Gastroenterol, 44
Duverlie (1998)
Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivityJ Gen Virol, 79
Conjeevaram (2006)
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Gastroenterology, 131
El-Shamy (2008)
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapyHepatology, 48
Chung (2009)
Treatment failure in hepatitis C: mechanisms of non-responseJ Hepatol, 50
Lin (2006)
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domainJ Virol, 80
Enomoto (1996)
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infectionN Engl J Med, 334
Watanabe (2001)
Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infectionJ Infect Dis, 183
Hayashi (2010)
Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon- alpha 2b and ribavirin combination therapyJ Viral Hepat
Gale (1998)
Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistanceClin Diagn Virol, 10
Veillon (2004)
Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirinPathol Biol, 52
Howell (2008)
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infectionClin Gastroenterol Hepatol, 6
Pawlotsky (2003)
Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis CAntiviral Res, 59
El-Shamy (2007)
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment seraMicrobiol Immunol, 51
Hadziyannis (2004)
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med, 140
Chen (2010)
Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapyJ Viral Hepat
Castelain (2002)
Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivityJ Infect Dis, 185
Hofmann (2005)
Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapyJ Clin Virol, 32
Pascu (2004)
Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differencesGut, 53
Chung (1999)
Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virusJ Med Virol, 58
Weigand (2007)
Treatment of hepatitis C virus infectionWorld J Gastroenterol, 13
Nousbaum (2000)
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapyJ Virol, 74
Summary. Several studies have reported correlation between mutations in core and NS5A proteins of hepatitis C virus (HCV) and response to interferon (IFN) therapy. In particular, mutations in NS5A protein have been shown to correlate with responsiveness to IFN treatment of HCV‐1b in Japanese patients. This study investigated whether amino acid (aa) mutations in the core and NS5A proteins of HCV‐1a, 1b, 3a, 3b and 6f correlated with the response to pegylated interferon (Peg‐IFN) plus ribavirin (RBV) therapy in Thai patients. The entire sequences of core and NS5A of HCV from 76 HCV‐infected patients were analysed in comparison with corresponding reference sequences. The data revealed that the number of aa mutations in full‐length NS5A, its C‐terminus, IFN sensitivity‐determining region, variable region 3 (V3) and V3 plus flanking region of HCV‐1b NS5A protein were significantly higher in responders than in the treatment failure group (P =0.010, 0.031, 0.046, 0.020 and 0.006, respectively). Similar results were found in a putative protein kinase R binding domain region in HCV‐6f NS5A protein (P =0.022). Moreover, specific aa substitutions in NS5A that appeared to be associated with responders or the treatment failure group were observed at positions 78 and 305 for HCV‐1b (P =0.028), 64 and 52 for HCV‐1a (P =0.033) and 6f (P =0.045). Nevertheless, analysis of aa sequences of core protein revealed highly conserved sequences among HCV genotypes and no significant differences between the viruses from responders and the treatment failure group. Our findings indicate that mutations in aa residues of NS5A of HCV‐1a, 1b and 6f correlated well with responsiveness to Peg‐IFN and RBV combination therapy.
Journal of Viral Hepatitis – Wiley
Published: Apr 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.